Global Hyperphosphatemia Drug Market Forecast 2018-2026
The global hyperphosphatemia drugs market is expected to grow at a CAGR of 16.06 % during the forecast period of 2018-2026. The market is expected to be worth $xx million by the year 2026. Increasing prevalence of chronic diseases, unmet medical needs, a high proportion of the elderly population and the rise in public awareness are the major drivers for the hyperphosphatemia drugs market.
The market segmentation is done on the basis of the formulation. The various types of phosphate binders include calcium-based phosphate binders, aluminium-based phosphate binders, magnesium-based phosphate binders, iron-based phosphate binders and other phosphate binders. Of these, the Calcium-based phosphate binder’s held the largest market share of xx% in 2017 and is expected to continue its dominance during the forecast period. The global hyperphosphatemia market is facing many restraints due to various limitations levied by the Food and Drug Administration (FDA) and the growing side effects of the hyperphosphatemia drugs observed in some patients. In spite of this, the Asia-Pacific hyperphosphatemia drug market is showing much promise in terms of making various opportunities available for the market to grow and expand.
The hyperphosphatemia drugs market in North America is expected to hold the largest share by the end of the forecast period due to changing dietary habits, increasing osteoporosis cases and a rising ageing population in this region. The Europe hyperphosphatemia drugs market is also fast growing at a CAGR of xx%. However, it is the Asia-Pacific market which is expected to propel the market growth, with the Indian hyperphosphatemia drugs market exhibiting the highest growth at a CAGR of xx% during the forecast period.
The major companies in the hyperphosphatemia drugs market include, Johnson And Johnson, Amag Pharmaceuticals, Cipla, Keryx Biopharmaceuticals, Sun Pharm Inc., Zeria Pharmaceutical, DSM Biotech Pharmacal , Ultragenyx, Fermenta Biotech Ltd, Pfizer Inc., Bruno Pharmaceutical Spa, Roche Diagnostics Corporation, Vifor Pharma, Sanofi R.H. Moore Drug Co., Shire, and Fresenius Medical Care.